Nordic AML Group

Germline Predisposition to Myeloid Neoplasms – Case discussions
2026-05-07 15:00 - 16:00, 2026-09-24 15:00 - 16:00, 2026-12-10 15:00 - 16:00 (Europe/Paris)
Join the MDR for patients with germline predisposition for hematological malignancies.
This meeting is for clinicians within the Nordics.via this Zoom-link.
If you want to discuss a case, please send 1-2 summary slides with the most important information to Panagiotis Baliakas (panagiotis.baliakas@igp.uu.se), Uppsala, Sweden.

NAMLG meeting @ EHA2026
2026-06-13 00:30 - 14:00 | EHA Meeting Hub, rooms K18 + K19
Agenda – 2026-06-13 – NAMLG meeting
Welcome to our meeting @ EHA June 13 @ 12:30 – 14:00 at EHA Meeting Hub, rooms K18 + K19.
Agenda

1. Approval of Minutes from Last Meeting
2. Planning 2027 NAMLG Election
3. Nordic AML Meeting 2026 in Bergen – Update and Promotion
4. LD VenEx Trial – Status and Progress
5. Grant Applications

a. Nordic Cancer Union – TP53+ in myeloid neoplasia
b. Mission Cancer (Phase 1)
c. Others?

6. Nordic Molecular Tumor Board & Biobanks [chair Kim Theilgaard-Mönch]

a. How to build a Nordic Molecular Tumor Board for AML by Janne Lehtiö, Karolinska Institutet
b. Discussion

7. UK Clinical Trials – Orientation and Collaboration

a. APL
b. FLT3+

8. Other Business and Closing

AML Course Day 2026 - Bergen
2026-09-16 08:00 - 17:00

Nordic AML Meeting 2026 - Bergen
2026-09-17 - 2026-09-18

Otsuka - Webinar - Treatment options for fragile AML patients
2026-09-17 16:30 - 17:30
Find more information and register using this link.
16.30 | Welcome, Ivar Haukeland, Brand Manager, Otsuka Pharma Scandinavia AB
16.35 | Early Nordic experience with AML therapies, Professor Bjørn Tore Gjertsen, Bergen
16.55 | The evolving AML treatment landscape, Professor Gail Roboz, New York.
17.20 | Questions and discussion, led by Professor Bjørn Tore Gjertsen, Bergen
